Streetbeat News

Earnings

RKDA

Arcadia Biosciences (NASDAQ:RKDA) reported Q4 earnings with an EPS of $-2.1, beating estimates by 19.0% against an expected $-2.58. Revenue increased by $170 thousand from the same period last year. Despite beating EPS estimates last quarter, RKDA's share price dropped by 3.0% the following day. The company's past earnings performance shows a mixed trend with both beats and misses on EPS and revenue estimates.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:30 pm

RKDA

Arcadia Biosciences reported Q4 earnings with a loss of $2.10 per share, surpassing the expected $2.58 loss, marking a 66.72% improvement from last year. However, their sales of $1.17M fell short of the $1.75M forecast, despite being a 17% increase from the previous year.

Portfolio Pulse from dijoy@benzinga.com

March 28, 2024 | 9:27 pm

BNR

Burning Rock Biotech (NASDAQ:BNR) reported a Q4 EPS of $(0.22), improving from $(0.31) YoY, but saw a decrease in sales to $17.10M from $20.62M YoY.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 9:23 pm

CPTN

Cepton (NASDAQ:CPTN) reported Q4 earnings with an EPS of $-0.41, beating estimates by 45.0% against an expected $-0.74. Revenue increased by $3.38 million from the same period last year. Despite beating EPS estimates in the past, such as last quarter's beat by $0.34, Cepton's share price dropped by 5.0% the following day. The company has shown a pattern of surpassing EPS estimates but faces volatility in share price post-earnings announcement.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:20 pm

CPTN

Cepton (NASDAQ:CPTN) reported Q4 earnings with losses of $(0.41) per share, surpassing the $(0.74) estimate, and sales of $4.95M, exceeding the $2.46M estimate. This represents significant improvements over the previous year.

Portfolio Pulse from dijoy@benzinga.com

March 28, 2024 | 9:16 pm

AXDX

Accelerate Diagnostics (NASDAQ:AXDX) reported Q4 earnings with an EPS of $-0.89, missing estimates by -44.0%. Revenue increased by $55 thousand from the previous year. The company has a history of missing EPS estimates, which previously led to a 3.0% drop in share price.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:15 pm

AXDX

Accelerate Diagnostics (NASDAQ:AXDX) reported Q4 earnings with a loss of $(0.89) per share, missing the $(0.62) estimate, and sales of $3.03M, below the $3.45M estimate. This represents a 493.33% increase in losses and a 1.85% increase in sales year-over-year.

Portfolio Pulse from dijoy@benzinga.com

March 28, 2024 | 9:13 pm

DLPN

Dolphin Entertainment (NASDAQ:DLPN) reported a significant increase in quarterly losses to $(0.54) per share from $(0.21) YoY, despite beating sales estimates with $12.00M against the expected $11.10M. This represents a 157.14% increase in losses and a 7.73% increase in sales compared to the same period last year.

Portfolio Pulse from dijoy@benzinga.com

March 28, 2024 | 9:06 pm

ZVRA

Zevra Therapeutics (NASDAQ:ZVRA) reported Q4 earnings with a -48.0% miss on estimated earnings, posting an EPS of $-0.4 against an estimate of $-0.27. Revenue increased by $10.92 million from the same period last year. Despite missing EPS estimates last quarter, the share price increased by 1.0% the following day.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:05 pm

TENX

Tenax Therapeutics (NASDAQ:TENX) reported Q4 earnings with an EPS of $-11.84, missing estimates by -45.0% against an expected $-8.14. Revenue remained unchanged from the previous year. This follows a quarter where the company beat EPS estimates but saw a 19.0% drop in share price the next day.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 9:05 pm